# FDA 483 - Nancy Kim, M.D. - March 25, 2022

Source: https://www.globalkeysolutions.net/records/483/nancy-kim-md/745460e3-0f68-4b66-a1c0-5c3dcdb83709

> FDA 483 for Nancy Kim, M.D. on March 25, 2022. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Nancy Kim, M.D.
- Inspection Date: 2022-03-25
- Product Type: drugs
- Office Name: Division of Pharmaceutical Quality Operations IV
- Summary: An FDA inspection of Nancy Kim, M.D., a clinical investigator in Scottsdale, AZ, revealed significant deviations from investigational plans and protocols. The investigator failed to personally conduct required study assessments, delegated duties to non-delegated staff, and allowed staff to use her login credentials for data entry. Additionally, the inspection found a dosing error involving an incorrect investigational product and a failure to report this and other dispensing errors to the sponsor in a timely manner.

## Related Officers

- [Bioresearch Monitoring Specialis](https://www.globalkeysolutions.net/people/denise-l-burosh/075a442f-67e0-4a65-9c09-e8819a329773)

Company: https://www.globalkeysolutions.net/companies/nancy-kim-md/b0a9c11e-9a3d-4b02-824a-583471e765a6

Office: https://www.globalkeysolutions.net/offices/division-of-pharmaceutical-quality-operations-iv/a2d2ff91-dc0f-433e-b91f-ca90ff8998b6